American Heart Association. “Cholesterol-Lowering Medications.” Diakses Juni 2026.
British Heart Foundation. “Statins: Your Questions Answered.” Diakses Juni 2026.
Blumenthal, Roger S., et al. “2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline for the Management of Patients With Dyslipidemia.” Journal of the American College of Cardiology (2026).
Wiggins, Barbara S., et al. “2026 Dyslipidemia Guideline-at-a-Glance.” Journal of the American College of Cardiology (2026).
Cholesterol Treatment Trialists’ Collaboration. “The Effects of Lowering LDL Cholesterol with Statin Therapy in People at Low Risk of Vascular Disease: Meta-analysis of Individual Data from 27 Randomised Trials.” The Lancet 380, no. 9841 (2012): 581–590.
Giral, Philippe, Joël Coste, Julie Weill, et al. “Cardiovascular Effect of Discontinuing Statins for Primary Prevention at the Age of 75 Years: A Nationwide Population-Based Cohort Study in France.” European Heart Journal 40, no. 43 (2019): 3516–3525.
Daskalopoulou, Stella S., Joseph A. Delaney, Kristian B. Filion, et al. “Discontinuation of Statin Therapy Following an Acute Myocardial Infarction: A Population-Based Study.” European Heart Journal 29, no. 17 (2008): 2083–2091.
Newman, Connie B., David Preiss, Jennifer A. Tobert, et al. “Statin Safety and Associated Adverse Events: A Scientific Statement from the American Heart Association.” Arteriosclerosis, Thrombosis, and Vascular Biology 39, no. 2 (2019): e38–e81.
Cheeley, Megan K., Terry A. Jacobson, Christie M. Maki, et al. “NLA Scientific Statement on Statin Intolerance: A New Definition and Key Considerations for ASCVD Risk Reduction in the Statin Intolerant Patient.” Journal of Clinical Lipidology 16, no. 4 (2022): 361–375.
U.S. Food and Drug Administration. “Statins: Drug Safety Communication—FDA Requests Removal of Strongest Warning Against Using Cholesterol-Lowering Statins During Pregnancy.” Diakses Juni 2026.